My Watchlist

Top Indices

Nasdaq Composite

SPX

My Portfolio

Ascendis Pharma A/S - Ordinary Share (NQ:ASND)

217.31 +7.52 (+3.58%)

Streaming Delayed Price Updated: 11:42 AM EDT, Jun 11, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Ascendis Pharma A/S - Ordinary Share

< Previous 1 2 3 4 5 6 7 8 9 Next >

The Daily Biotech Pulse: ObsEva Surges On Out-Licensing Deal, EyeGate Appoints New CEO, 2 Positive Catalysts For Merck, Candel Therapeutics Debuts ↗

July 27, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 26) Absci, CORP (NASDAQ: ABSI...

Via Benzinga

Expert Ratings For Ascendis Pharma ↗

July 21, 2021

Ascendis Pharma (NASDAQ:ASND) has observed the following ...

Via Benzinga

The Daily Biotech Pulse: Acorda Spikes On Distribution Deal, Alzamend Soars On Data, Pfizer-BioNTech To Supply More Vaccine Doses, 3 IPOs ↗

July 23, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 22) Bio-Techne Corporation (...

Via Benzinga

The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs ↗

June 20, 2021

Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries.

Via Talk Markets

The Daily Biotech Pulse: Ardelyx Sinks On Regulatory Setback, AnPac Issues Positive Preannouncement, European Nod For Myovant, HCW Biologics Debuts On Wall Street ↗

July 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs July 19) Cytokinetics, Incorporated...

Via Benzinga

The Week Ahead In Biotech: Incyte, Ascendis FDA Decisions, Liver Congress Presentations And 4 IPOs ↗

June 20, 2021

Biotech stocks came under pressure in the week ended June 18, dragged by the negative sentiment that prevailed in the broader market due to macroeconomic worries. The U.S. Federal...

Via Benzinga

Ascendis Pharma's TransCon hGH FDA Review Pushed Backed By Three Months ↗

June 14, 2021

The FDA has extended the ongoing review of the marketing application of Ascendis Pharma A/S's (NASDAQ: ASND) TransCon hGH (lonapegsomatropin) for the...

Via Benzinga

Attention Biotech Investors: Mark Your Calendar For June PDUFA Dates ↗

June 01, 2021

The FDA review machinery worked overtime in May, completing reviews of several drug applications. Except for stray rejections or delays, the agency churned out mostly positive...

Via Benzinga

What 5 Analyst Ratings Have To Say About Ascendis Pharma ↗

June 01, 2021

Ascendis Pharma (NASDAQ:ASND) has observed the following analyst ratings within the last quarter: Last 30 Days 1 Month Ago 2 Months Ago 3 Months Ago Bullish 1 0 0 1...

Via Benzinga

Earnings Scheduled For June 1, 2021 ↗

June 01, 2021

Companies Reporting Before The Bell • 36KR Holdings (NASDAQ:KRKR) is expected to report quarterly loss at $0.11 per share on revenue of $10.82 million. • Canopy...

Via Benzinga

Ascendis Pharma A/S (ASND) Q1 2021 Earnings Call Transcript ↗

May 28, 2021

ASND earnings call for the period ending March 31, 2021.

Via The Motley Fool

Topics Earnings

The Week Ahead In Biotech (May 23-29): Eton, Lantheus FDA Decisions, Adcom Test For Provention, Chiasma Data Presentation ↗

May 23, 2021

Biotech stocks advanced in the week ended May 21, as risk aversion forced traders to buy into defensives. As earnings news flow tapered, stocks took cues from clinical readouts....

Via Benzinga

The Daily Biotech Pulse: Vir-GlaxoSmithKline COVID-19 Antibody Treatment Approved, Zosano Spikes On Long-Term Migraine Drug Data, Decision Day For Eton, 2 IPOs ↗

May 27, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 26) I-Mab (NASDAQ: IMAB)...

Via Benzinga

Ascendis Pharma's TransCon PTH Provides Durable Benefit, Is Well Tolerated Even After One Year Treatment In Hypoparathyroidism ↗

May 11, 2021

Ascendis Pharma A/S (NASDAQ: ASND) has announced preliminary 58-week results from the continuing open-label extension (OLE) portion of the Phase 2 PaTH...

Via Benzinga

Stocks That Hit 52-Week Lows On Monday ↗

April 19, 2021

During Monday's morning trading, 29 companies set new 52-week lows. Intriguing Points: Ascendis Pharma (NASDAQ:ASND) is the largest company in terms of market...

Via Benzinga

Earnings Scheduled For May 27, 2021 ↗

May 27, 2021

Companies Reporting Before The Bell • Royal Bank of Canada (NYSE:RY) is likely to report quarterly earnings at $2.48 per share on revenue of $11.77 billion. •...

Via Benzinga

The Daily Biotech Pulse: FDA Authorizes Pfizer-BioNTech COVID-19 Vaccine For Adolescents, Lilly Strikes R&D Collaboration, Vaccine Stocks Novavax, Inovio Sink On Earnings ↗

May 11, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs May 10) AbbVie Inc. (NYSE: ABBV) -...

Via Benzinga

The Daily Biotech Pulse: Q1 Beat From Johnson & Johnson, KalVista Study Placed On Hold, European Label Expansion For GW Pharma's Epidiolex ↗

April 20, 2021

Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech Stocks Hitting 52-week Highs April 15) Alexion Pharmaceuticals,...

Via Benzinga

< Previous 1 2 3 4 5 6 7 8 9 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.